News

News 05.06.2020 Schlieren, Switzerland – 4 June 2020 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and immune repertoire analysis, today announces that it has identified several SARS-CoV-2-specific virus-neutralizing antibodies with the potential for development as a COVID-19 immunotherapy. MTx’s DROPZYLLA® platform isolated ultra-rare and highly potent...

Events, Internal events
Event date: 10.06.2020 Wed, Jun 10, 2020 8:30 AM - 9:30 AM CEST Registration: https://register.gotowebinar.com/register/1773650101719810572 Methods from the fields of Machine Learning and Artificial Intelligence have been applied successfully in many different domains and industries. The health sector is no exception to this. The digitisation of medical records and diagnostic data along with the increasing...

News 26.05.2020 Zurich-Schlieren, May 26, 2020. Proteomedix, the Swiss cancer diagnostics company is pleased to announce the appointment of Dr Maurizio Ballerini, MD as VP Market Development EMEA and Dr Helene Peyro Saint-Paul, MD, as Medical Advisor effective June 1, 2020. These accomplished executives bring a wealth of industry expertise to the...

News 19.05.2020 Zurich-Schlieren, Switzerland, May 19, 2020. Proteomedix, the Swiss cancer diagnostics company announces today the publication of the analytical performance results of Proclarix, Proteomedix lead product for improved prostate cancer diagnostics in the peer-reviewed journal PLOS ONE. The report published today highlights the analytical performance of the two CE-IVD assays that measure...

News 15.05.2020 Zurich-Schlieren, Switzerland, May 15, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced the presentation of preclinical data from three of the company’s programs at the American Academy for Cancer Research (AACR) Virtual Annual Meeting II, June...